SolasCure Awarded £405K Innovate UK Biomedical Catalyst Grant to Advance Chronic Wound Care

Funding will be used to further optimize Aurase Wound Gel for future clinical trials SolasCure aims to deliver the first efficacious, cost-effective, and pain-free solution for millions of patients suffering…

Continue ReadingSolasCure Awarded £405K Innovate UK Biomedical Catalyst Grant to Advance Chronic Wound Care

SolasCure announces final closing of GBP 10.9m (c. USD 13.3m) Series B fundraise to advance wound care innovation

Funding will support the development of Aurase Wound Gel and progress towardfurther Phase II clinical trials of innovative wound debriding enzyme Cambridge, UK 27 March 2023 – SOLASCURE Ltd (SolasCure),…

Continue ReadingSolasCure announces final closing of GBP 10.9m (c. USD 13.3m) Series B fundraise to advance wound care innovation

SolasCure named a UK Life Sciences Innovator 2023 by the UK’s Department for International Trade

SolasCure, a Cambridge-based biotech company developing revolutionary wound-cleaningtechnology, has been named a UK Life Sciences Innovator in a showcase sponsored by the UK’sDepartment for International Trade. Following a rigorous application process,…

Continue ReadingSolasCure named a UK Life Sciences Innovator 2023 by the UK’s Department for International Trade

SolasCure announces publication of toxicology and pre-clinical research programme as final patient is enrolled into pivotal clinical trial

Innovative Cambridge biotech company SolasCure, which is developing a revolutionarywound cleaning technology, has published its pre-clinical results with the InternationalWound Journal, showing preliminary evidence that supports its new enzymatic debridementproduct…

Continue ReadingSolasCure announces publication of toxicology and pre-clinical research programme as final patient is enrolled into pivotal clinical trial

SolasCure’s David Fairlamb recognised at TOPRA Awards for exceptional leadership in regulatory strategy

David Fairlamb, Director of Regulatory Affairs at SolasCure, has been named as a winner at the TOPRA awards. The awards, organised by The Organisation for Professionals in Regulatory Affairs, are…

Continue ReadingSolasCure’s David Fairlamb recognised at TOPRA Awards for exceptional leadership in regulatory strategy

SolasCure wins 1st place at prestigious EIT Health Catapult biotech competition for investigational wound care product Aurase Wound Gel

SolasCure has been named the winner of the biotech category at the EIT Health Catapult finals in Stockholm. The medical use of Aurase Wound Gel is being developed with the…

Continue ReadingSolasCure wins 1st place at prestigious EIT Health Catapult biotech competition for investigational wound care product Aurase Wound Gel
Read more about the article Cambridge biotech company earns international recognition as first trial patient receives treatment
Back View of Team of Senior and Young Scientists Working on Problem Solution. They're Looking for Information on a Computer. Their Laboratory is Ulta Modern.

Cambridge biotech company earns international recognition as first trial patient receives treatment

SolasCure, a Cambridge-based biotech company developing revolutionary wound-cleaning technology, has seen its first trial patient receive treatment. Leveraging biomimicry and evidence-based medicine, the pioneering biologics company is developing its first…

Continue ReadingCambridge biotech company earns international recognition as first trial patient receives treatment